A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy

To be part of this study, you would typically need to meet certain conditions. First, you must have a confirmed diagnosis of Spinal Muscular Atrophy (SMA) that's been checked by genetic tests, and you should be between 4 and 21 years old. It doesn't matter if you can walk or not; both ambulant and non-ambulant individuals can be considered. A key requirement is that you are already on a stable dose of an existing SMA treatment, such as nusinersen, risdiplam, or have previously received onasemnogene abeparvovec, and you expect to continue with that treatment throughout the study.

There are also some reasons why someone might not be able to join. For example, if you have already tried other medicines that block myostatin, you wouldn't be eligible for this study. Your weight must be at least 15 kilograms. Also, if you need a machine to help you breathe during the day while you're awake, you wouldn't be able to participate (though using a breathing machine overnight or for naps is usually fine). If you've had spinal fusion surgery in the last six months, or if you have certain types of implanted medical devices in your brain or spine, you would also be excluded.

If you decide to take part in this study, you would likely have a series of visits to the study clinic. These visits would involve various assessments to check your muscle strength, movement, and overall health. You would receive either the study medicine, taldefgrobep alfa, or a placebo (a dummy treatment) through injections. The study team would closely monitor your health and any changes you experience throughout the trial. They'll also check your blood or other samples from time to time. The exact number of visits, tests, and the total length of your involvement would be fully explained by the study team before you make any decisions.